Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years

Marie C. Hogan, Tetyana V. Masyuk, Linda Page, David R. Holmes, Xujian Li, Eric J. Bergstralh, Maria V. Irazabal, Bohyun Kim, Bernard F. King, James F. Glockner, Nicholas F. Larusso, Vicente E. Torres

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


Background. We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR®) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth in patients with severe isolated PLD. We have now completed an open-label extension for one additional year to assess safety and clinical benefits of continued use of OctLAR for 2 years (O→O) and examined drug effect in the placebo group who crossed over to OctLAR in Year 2 (P→O). Methods. The primary end point was change in total liver volume (TLV) measured by magnetic resonance imaging (MRI); secondary end points were changes in total kidney volume (TKV) measured by MRI, glomerular filtration rate (GFR), quality of life (QOL), safety, vital signs and laboratory parameters. Results. Forty-one of 42 patients received OctLAR (n = 28) or placebo (n = 14) in Year 1 and received OctLAR in Year 2 (maximum dose 40 mg). Patients originally randomized to placebo (P→O) showed substantial reduction in TLVafter treatment with OctLAR in Year 2 (δ%-7.66 ± 9.69%, P = 0.011). The initial reduction of TLV in the OctLAR group (O→O) was maintained for 2 years (δ%-5.96 ± 8.90%), although did not change significantly during Year 2 (δ%-0.77 ± 6.82%). OctLAR inhibited renal enlargement during Year 1 (δ% +0.42 ± 7.61%) in the (O→O) group and during Year 2 (δ%-0.41 ± 9.45%) in the (P→O) group, but not throughout Year 2 (δ% +6.49 ± 7.08%) in the (O→O) group. Using pooled analyses of all individuals who received OctLAR for 12 months, i.e. in Year 1 for O→O patients and Year 2 for P→O patients, average reduction in TLV was-6.08 ± 7.58% (P = 0.001) compared to net growth of 0.9 ± 8.35% in the original placebo group. OctLAR-treated individuals continued to experience improvements in QOL in Year 2, although overall physical and mental improvements were not significant during Year 2 compared to Year 1. Changes in GFR were similar in both groups. Conclusion. Over 2 years, OctLAR significantly reduced the rate of increase in TLV and possibly the rate of increase in TKV.

Original languageEnglish (US)
Pages (from-to)3532-3539
Number of pages8
JournalNephrology Dialysis Transplantation
Issue number9
StatePublished - Sep 2012


  • chronic kidney disease
  • kidney volume
  • liver cyst
  • polycystic kidney disease
  • somatostatin analogs

ASJC Scopus subject areas

  • Nephrology
  • Transplantation


Dive into the research topics of 'Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years'. Together they form a unique fingerprint.

Cite this